What We're Reading: Page
Industry reads hand-picked by our editors
Apr 20, 2023
Apr 19, 2023
-
Bloomberg
Big Drugmakers Like Merck Are Forced to Pay Up in M&A for R&D Neglect
-
The Wall Street Journal
Unexpected Ozempic Side Effect? Weird Dreams
-
C&EN
Generative AI is dreaming up new proteins
Apr 18, 2023
-
Fierce Pharma
Struggling Gamida wins long-awaited FDA approval for Omisirge
-
FirstWord Pharma
Lilly pours another $1.6 billion to buoy drug manufacturing in home base
-
Bloomberg
Danaher Is Said to Shelve Takeover Pursuit of Catalent
-
Regulatory Focus
ORA head says attrition is outpacing hiring, decries flat funding for inspections
Apr 17, 2023
-
The Wall Street Journal
Demand for Obesity Drugs Has Insurers Paying Close Attention
-
Reuters
GSK’s antibiotic drug to treat uncomplicated UTIs meets main goals
-
Financial Times
Gates Foundation makes unusual investment in experimental cancer trial
-
The New York Times
CoolSculpting Promised to Zap Fat. For Some, It Brought Disfigurement.
Apr 14, 2023
-
LifeSciVC
Biotech Funding: Times Are Tough, Maybe For The Better
-
Science
Judicial interference with mifepristone
-
Bloomberg
Biden’s Medicare Chief Is Crafting How Program Will Negotiate Drug Prices
-
Generative AI is dreaming up new proteins
Apr 13, 2023
-
STAT
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
-
KFF Health News
The Drug Company That Prospered Without Creating Any Drugs
-
Bloomberg
Zealand Pharma Taps Centerview to Explore Partnership Deals
-
The New York Times
Inside the Online Market for Overseas Abortion Pills
Apr 12, 2023
-
NBC News
Cancer drug shortages are creating dire circumstances for some patients
-
Boston Business Journal
More layoffs hit Biogen as drugmaker cuts multiple sclerosis team
-
CNN
Biden administration declares fentanyl laced with xylazine ‘an emerging threat’ in the US
-
Healthcare Dive
Last year was second-best year for healthcare PE deals, Bain finds
Previous
